Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma.
#NETSPOT NUCLEAR MEDICINE UPDATE#
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Beauregard JM, Hofman MS, Kong G, Hicks RJ. Scintigraphy and radionuclide therapy with -octreotide. Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Virgolini I, Ambrosini V, Bomanji JB, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. Sandström M, Velikyan I, Garske-Román U, et al. Measured human dosimetry of 68Ga-DOTATATE. Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M.
Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol 2012 9(12):712–720. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Krenning EP, Bakker WH, Breeman WA, et al. It also allows optimal patient management, including theranostic application of peptide receptor radionuclide therapy, and the restaging of patients following therapy. The use of GaTate PET/CT together with FDG PET/CT allows identification of tumor heterogeneity, which provides prognostic information and can be pivotal in guiding biopsy. They also highlight the complementary role of 2-fluoro-2-deoxy- d-glucose (FDG) PET/CT, including the advantages of using both GaTate PET/CT and FDG PET/CT to evaluate sites of well- and poorly differentiated disease. In addition, they discuss potential causes of false-positive findings, including pancreatic uncinate process activity, inflammation, osteoblastic activity, and splenosis. The authors discuss the normal appearance at GaTate PET/CT and the utility of this modality in a variety of these tumors, including gastrointestinal, pancreatic, and bronchial NETs as well as pheochromocytoma, paraganglioma, meningioma, and oncogenic osteomalacia. GaTate PET/CT allows whole-body imaging of cell surface expression of somatostatin receptors (SSTRs) and is rapidly evolving as the new imaging standard of reference for the detection and characterization of NETs. Food and Drug Administration, thereby increasing interest in and availability of this radiotracer. GaTate, a somatostatin analog, has recently been accorded orphan drug status by the U.S. Gallium 68 ( 68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) is an imaging technique for detecting and characterizing neuroendocrine tumors (NETs).
0 kommentar(er)
